ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors
Sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant benefits for adults aged 80 years and older with chronic kidney disease (CKD), according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 21 to 25 in Denver.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Researchers uncover how astrovirus spreads without destroying gut cells
United Kingdom
-
Hospital-acquired anemia common among ICU patients
United Kingdom
-
Rutgers-led team secures $6.5 million grant for lung cancer research
United Kingdom
-
Hospital admission rates vary widely across England's emergency departments
United Kingdom
-
Study reveals potential link between limited cold stress during pregnancy and birth weight
United Kingdom
-
Autism diagnosis patterns change as psychiatric profiles shift across Europe
United Kingdom
-
AlphaFold3 reveals molecular interactions driving T cell recognition
United Kingdom
-
Historically redlined neighborhoods report higher opioid overdose death rates
United Kingdom